#Denmark #Copenhagen #Glioblastoma #Curasight #uTREAT

Curasight's Significant Breakthrough in Brain Cancer Treatment

Curasight A/S, a pioneering company in radiopharmaceuticals, has marked a significant achievement in the fight against brain cancer. The company recently announced the successful administration of the first dose in its Phase 1 clinical trial for uTREAT®, specifically targeting glioblastoma, the most aggressive form of brain cancer. This first dosing represents not only a vital milestone for Curasight as a clinical-stage therapeutic company but also a beacon of hope for patients facing this challenging diagnosis.

Understanding the Trial and Its Importance

The trial aims to evaluate uTREAT as a new category of targeted radiopharmaceutical therapy. Glioblastoma patients, particularly those newly diagnosed or suspected of having the condition, are participating in this pioneering study. Curasight’s uTREAT represents an innovative approach to treating an illness that has long evaded effective solutions. Ulrich Krasilnikoff, CEO of Curasight, emphasizes the importance of this step, stating, "The dosing of the first patient with uTREAT in this Phase 1 trial marks an important step in the development of the therapeutic arm of our theranostic platform."

The uPAR Theranostic Platform

Curasight operates utilizing a unique theranostic platform that integrates two critical technologies: uTRACE and uTREAT. While uTRACE focuses on sensitive imaging for diagnosis using the uPAR receptor, uTREAT is differentiated by offering targeted treatment solutions. This coordination is intended to elevate the standards of diagnosis and treatment for uPAR-expressing cancers, which includes glioblastoma.

The Challenge of Glioblastoma

Glioblastoma multiforme presents a dire challenge in cancer treatment, significantly impacting life expectancy. Approximately 65,000 patients in the United States and the EU receive a diagnosis for primary brain tumors each year, with glioblastoma accounting for over half of these cases. The prognosis remains grim, as statistics reveal that around 50% of patients succumb to the disease within 14 months of diagnosis, and only 5% survive beyond five years. Current standard treatments typically involve external beam radiation, which while effective, can have detrimental side effects on healthy brain tissue. Curasight’s uTREAT aims to enhance treatment precision, potentially reducing the collateral damage to healthy areas of the brain.

Future of uTREAT

The commencement of the Phase 1 trial not only marks progress in the clinical evaluation of uTREAT but also signals Curasight's commitment to actively contributing to the realm of cancer treatment. Meanwhile, their diagnostic platform, uTRACE, continues to undergo exploration in a Phase 2 trial focused on prostate cancer in collaboration with Curium Inc. This integrated approach by Curasight brings hope to refining both diagnosis and treatment rituals, paving the path for a future where patients with aggressive cancers can have access to more promising treatment avenues.

As the trial progresses, Curasight encourages active collaboration and support from the medical community, a vital component in fostering advancements in therapeutic techniques. Through initiatives like the uTREAT trial, Curasight not only aims to redefine therapeutic options in oncology but to also instill a renewed sense of hope among patients and their families who grapple with the challenges posed by glioblastoma and other high-grade gliomas.

For more information and future updates regarding Curasight’s trials and their implications in cancer treatments, please feel free to connect with the company.

• ---

For inquiries, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
Email: [email protected]
Website: www.curasight.com